This event showcased top chemical biology research from labs at Oxford. Particular emphasis was placed on linking basic chemical biology research to work in the clinic.
11 top speakers from departments across Oxford gave very different talks touching on disease-agnostic technologies and drug discovery platforms, target and pathway expertise, and validating hypotheses in the clinic. Two industry experts also gave their viewpoints and highlights of successful academia-industry collaboration.
Our industry guests were unanimously impressed with the diversity and quality of research taking place at Oxford, as well as our collaborative approach.
“I liked the breadth and high quality of the presentations.”
“Great academic work being done at Oxford University.”
“It‘s great to see Oxford leading the way to interact with industry.”
“The sense of collaboration (internally and externally) at Oxford was encouraging to see.”
The symposium brought together over 180 delegates including Oxford researchers, industry colleagues and technology transfer professionals. In doing so, it provided the ideal forum for discussion and will lead to lasting collaborative relationships.
Industry delegates reported 49 new research connections with academics at Oxford.
“I had an invaluable introduction and 1:1 with a researcher from a major pharma company in which we discussed potential collaboration.”
Oxford delegates reported 24 new research connections with colleagues in Industry.
“The one-to-one meetings with academics not previously known to me were a great way to initiate discussion.”
Following the presentations, delegates were invited to participate in an interactive discussion entitled “How can Oxford best help industry translate new ideas into pioneer medicines?”
Professor Chris Schofield chaired a panel of four experts from Oxford and Industry with strong track records of academia-industry collaboration.
The discussion was vibrant, with the audience posing a range of interesting questions to the panel. Key themes that emerged throughout were the importance of communication, training and industry-guided research facilitation in academia.
“Some of the comments and questions during the roundtable discussion were really interesting. I've wanted to have this debate in Oxford for years!!”
“The round table discussions with industry representatives explaining how they interact with academia were illuminating.”
The Medical Research Council (MRC) improves human health through world class medical research. The MRC Proximity to Discovery: Industry Engagement Fund provides funding for innovative ways to enable to initial development of academic-industry collaborations.
The Higher Education Funding Council For England (HEFCE) provides funding for knowledge exchange through Higher Education Innovation Funding (HEIF). HEIF supports and develops a broad range of knowledge-based interactions between universities and colleges and the wider world. These collaborations benefit the UK economically and socially.
Research interests: Using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients.
Research interests: Nucleic acid chemistry, DNA sequence recognition and application of nucleic acids to nanotechnology, diagnostics and biology.
Research interests: Phenotypic screening and the UK National Phenotypic Screening Centre.
Research interests: The Eggeling laboratory focuses on the application and development of advanced ultra-sensitive, live-cell fluorescence microscopy techniques, such as optical super-resolution microscopy or nanoscopy featuring a spatial resolution down to the molecular level, superior to conventional optical microscopes. These super-resolution microscopes are optimized and used to unravel nanoscopic changes at the molecular level in living cells following cellular immune responses, such as T-cell activation.
Research interests: My lab studies the role of monocytes and macrophages in the initiation and resolution of chronic inflammation. We are particularly interested in the role chemokines and other chemoattractants play in atherosclerosis - a disease process in arteries that leads to angina, heart attacks and strokes.
Research interests: Laboratory and clinical research to better understand the molecular basis of tumour cell resistance to radiation treatment with the long term aim of developing treatments to make radiotherapy more effective.
Research interests: Seeking new targets for therapy in Alzheimer's disease by understanding basic mechanisms, in disease modification trials and experimental medicine and in the search for biomarkers for early diagnosis.
Research interests: Identifying drugs to target steps in the pathogenic cascade of lysosomal disorders, and testing them as mono-therapies or in combination with other therapies. Evaluating these in a pre-clinical setting before conducting translational studies in patients with clinical collaborators.
Research interests: Current projects involve investigations into how human cells respond to variations in oxygen supply, how complex antibiotics are made by biosynthesis in a few steps, how small molecules regulate transcription in humans, and on the chemical basis of epigenetics.
Research interests: Identifying the earliest pathological pathways activated in motor neuron disease in order to define the most therapeutically tractable areas for drug therapy and to apply these findings to clinical studies in patients.
Research interests: Understanding molecular mechanisms of age-related neurodegenerative diseases to generate novel molecular therapies.
Research interests: Resolving structural details of membrane peptides and proteins at high resolution.
Research interests: Stem cell technologies and stem cell based screening platforms.